Marc Martens

2.0k total citations · 1 hit paper
9 papers, 1.5k citations indexed

About

Marc Martens is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Law. According to data from OpenAlex, Marc Martens has authored 9 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Law. Recurrent topics in Marc Martens's work include Sarcoma Diagnosis and Treatment (3 papers), HER2/EGFR in Cancer Research (3 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). Marc Martens is often cited by papers focused on Sarcoma Diagnosis and Treatment (3 papers), HER2/EGFR in Cancer Research (3 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). Marc Martens collaborates with scholars based in Belgium, Netherlands and United Kingdom. Marc Martens's co-authors include Sigrid Stroobants, Saša Dimitrijević, Sandra Silberman, Raf Sciot, Allan T. van Oosterom, Jaap Verweij, Ole S. Nielsen, M. van Glabbeke, Ian Judson and Eugenio Donato Di Paola and has published in prestigious journals such as The Lancet, Cancer Research and Annals of Oncology.

In The Last Decade

Marc Martens

9 papers receiving 1.4k citations

Hit Papers

Safety and efficacy of imatinib (STI571) in metastatic ga... 2001 2026 2009 2017 2001 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
    2001 975 citations Allan T. van Oosterom, Ian Judson et al. The Lancet profile →

Peers

Marc Martens
Rodrigo Ruiz‐Soto United States
César Serrano Spain
Amy Harlow United States
Arin McKinley United States
Gina Z. D’Amato United States
Claudia Valverde Spain
Andreas H. Marx Germany
Yoshito Yamashita Japan
Heung-Moon Chang South Korea
Oliver Rosen United States
Rodrigo Ruiz‐Soto United States
Marc Martens
Citations per year, relative to Marc Martens Marc Martens (= 1×) peers Rodrigo Ruiz‐Soto

Countries citing papers authored by Marc Martens

Since Specialization
Citations

This map shows the geographic impact of Marc Martens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Martens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Martens more than expected).

Fields of papers citing papers by Marc Martens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Martens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Martens. The network helps show where Marc Martens may publish in the future.

Co-authorship network of co-authors of Marc Martens

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Martens. A scholar is included among the top collaborators of Marc Martens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Martens. Marc Martens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Denys, Hannelore, Marc Martens, Randal D’hondt, et al.. (2020). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Research and Treatment. 181(1). 97–105. 26 indexed citations
2.
Martens, Marc, et al.. (2013). The Link to the Subject-Matter of the Contract in Green and Social Procurement. European Procurement & Public Private Partnership Law Review. 8(1). 8–18. 3 indexed citations
3.
4.
Martens, Marc. (2007). Constitutional Right to a Healthy Environment in Belgium. Review of European Community & International Environmental Law. 16(3). 287–297. 3 indexed citations
5.
Dumez, Herlinde, Marc Martens, G. Guetens, et al.. (2006). Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anti-Cancer Drugs. 18(2). 211–218. 18 indexed citations
6.
Giaccone, Giuseppe, J.L. González-Larriba, A.T. van Oosterom, et al.. (2004). Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Annals of Oncology. 15(5). 831–838. 52 indexed citations
7.
Stroobants, Sigrid, J. Goeminne, Saša Dimitrijević, et al.. (2003). 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). European Journal of Cancer. 39(14). 2012–2020. 373 indexed citations
8.
Stroobants, Sigrid, J. Goeminne, Marc Martens, et al.. (2001). Early evaluation of tumour response to STI 571 with FDG-PET in patients with soft tissue sarcomas (STS). European Journal of Cancer. 37. S33–S34. 1 indexed citations
9.
Oosterom, Allan T. van, Ian Judson, Jaap Verweij, et al.. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. 358(9291). 1421–1423. 975 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rodrigo Ruiz‐Soto Breakdown of academic impact, for papers by César Serrano Breakdown of academic impact, for papers by Amy Harlow Breakdown of academic impact, for papers by Arin McKinley Breakdown of academic impact, for papers by Gina Z. D’Amato Breakdown of academic impact, for papers by Claudia Valverde Breakdown of academic impact, for papers by Andreas H. Marx Breakdown of academic impact, for papers by Yoshito Yamashita Breakdown of academic impact, for papers by Heung-Moon Chang Breakdown of academic impact, for papers by Oliver Rosen
Rankless by CCL
2026